Brokerages Expect Kiniksa Pharmaceuticals Ltd (KNSA) to Post ($0.50) Earnings Per Share

Share on StockTwits

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price objective of $31.33 for the company and are forecasting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also given Kiniksa Pharmaceuticals an industry rank of 92 out of 255 based on the ratings given to related companies.

A number of brokerages recently weighed in on KNSA. JMP Securities began coverage on shares of Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They issued an “outperform” rating and a $33.00 price target for the company. Wedbush began coverage on shares of Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They issued an “outperform” rating and a $31.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They issued an “overweight” rating and a $29.00 price target for the company. Finally, Goldman Sachs Group began coverage on shares of Kiniksa Pharmaceuticals in a research report on Monday, June 18th. They issued a “neutral” rating for the company.

Shares of KNSA opened at $24.34 on Monday. Kiniksa Pharmaceuticals has a 1-year low of $13.04 and a 1-year high of $24.64.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.53). sell-side analysts forecast that Kiniksa Pharmaceuticals will post -2.63 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hillhouse Capital Management Ltd. acquired a new position in Kiniksa Pharmaceuticals in the second quarter valued at $99,529,000. Baker BROS. Advisors LP acquired a new position in Kiniksa Pharmaceuticals in the second quarter valued at $52,050,000. Boxer Capital LLC acquired a new position in Kiniksa Pharmaceuticals in the second quarter valued at $20,346,000. FMR LLC acquired a new position in Kiniksa Pharmaceuticals in the second quarter valued at $14,565,000. Finally, VHCP Management II LLC acquired a new position in Kiniksa Pharmaceuticals in the second quarter valued at $11,091,000. Institutional investors own 34.91% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: NASDAQ

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply